Kbc Group Nv Uni Qure N.V. Transaction History

Kbc Group Nv

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Feb 15, 2024	SELL	$6.71 - $11.83 $4,213 - $7,429	-628 Reduced 20.19%	2,483 $17,000
Q3 2022 Feb 15, 2024	BUY	$16.98 - $25.54 $52,824 - $79,454	3,111 New	3,111 $58,000
Q2 2022 Feb 14, 2024	BUY	$13.15 - $20.45 $40,909 - $63,619	3,111 New	3,111 $58,000
Q2 2022 Jul 26, 2022	BUY	$13.15 - $20.45 $40,909 - $63,619	3,111 New	3,111 $58,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.